Citations

Clear

3314 citation(s) found for "Yu, Alexander".

Letter: Visual Field Defects in the Setting of Suprasellar Lesions: Could Vascularization Patterns of the Optic Chiasm Play a Role?
Agosti, Edoardo , Alexander, A. Yohan , Link, Michael J. , Meyer, Fredric B. , Peris‐Celda, Maria , Agosti, Edoardo , Alexander, A Yohan , Pinheiro‐Neto, Carlos

Mayo Clinic

Neurosurgery | June 21, 2022 | Volume: 91 | Issue: 3 | Pages: e102-e103

10.1227/neu.0000000000002069 | PMID 35876674 Get It

2022 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty
Goodman, Susan M. , Springer, Bryan D. , Davis, Marshall, Fernández, David , Figgie, Mark P. , Finlayson, Heather, George, Michael , Giles, Jon T. , Gililland, Jeremy M. , Klatt, Brian A., MacKenzie, Ronald, Russell, Linda , Sah, Alexander P. , Johnson, Beverly , Mandl, Lisa A. , Turgunbaev, Marat, Turner, Amy S. , Yates, Adolph J. , George, Michael , Giles, Jon T , Miller, Andy , Mandl, Lisa A , Turner, Amy S , Goodman, Susan M , Chen, Antonia F. , Fernández, David , Michaud, Kaleb D. , Abdel, Matthew P. , Sculco, Peter K. , Singh, Jasvinder A.

Mayo Clinic

Arthritis & Rheumatology | June 20, 2022 | Volume: 74 | Issue: 9 | Pages: 1464-1473

10.1002/art.42140 | PMID 35722708 Get It

Objective To develop updated guidelines for the perioperative management of disease‐modifying medications for patients with rheumatic diseases, specifically those with inflammatory arthritis (IA) and those with systemic lupus erythematosus (SLE), undergoing elective total hip arthroplasty (THA) or elective total knee arthroplasty (TKA). Methods We convened a panel of rheumatologists, orthopedic surgeons, and infectious disease specialists, updated the systematic literature review, and included currently available medications for the clinically relevant population, intervention, comparator, and outcomes (PICO) questions. We used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology to rate the quality of evidence and the strength of recommendations using a group consensus process. Results This guideline updates the 2017 recommendations for perioperative use of disease‐modifying antirheumatic therapy, including traditional disease‐modifying antirheumatic drugs, biologic agents, targeted synthetic small‐molecule drugs, and glucocorticoids used for adults with rheumatic diseases, specifically for the treatment of patients with IA, including rheumatoid arthritis and spondyloarthritis, those with juvenile idiopathic arthritis, or those with SLE who are undergoing elective THA or TKA. It updates recommendations regarding when to continue, when to withhold, and when to restart these medications and the optimal perioperative dosing of glucocorticoids. Conclusion This updated guideline includes recently introduced immunosuppressive medications to help decision‐making by clinicians and patients regarding perioperative disease‐modifying medication management for patients with IA and SLE at the time of elective THA or TKA.
2022 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty
Goodman, Susan M. , Springer, Bryan D. , Davis, Marshall, Fernández, David , Figgie, Mark P. , Finlayson, Heather, George, Michael , Giles, Jon T. , Gilliland, Jeremy, Klatt, Brian A., MacKenzie, Ronald, Russell, Linda , Sah, Alexander P. , Johnson, Beverly , Mandl, Lisa A. , Turgunbaev, Marat, Turner, Amy S. , Yates, Adolph J. , Gililland, Jeremy M. , George, Michael , Giles, Jon T , Miller, Andy , Mandl, Lisa A , Turner, Amy S , Goodman, Susan M , Chen, Antonia F. , Fernández, David , Michaud, Kaleb D. , Abdel, Matthew P. , Sculco, Peter K. , Singh, Jasvinder A.

Mayo Clinic

Arthritis Care & Research | June 20, 2022 | Volume: 74 | Issue: 9 | Pages: 1399-1408

10.1002/acr.24893 | PMID 35718887 Get It

ObjectiveTo develop updated guidelines for the perioperative management of disease‐modifying medications for patients with rheumatic diseases, specifically those with inflammatory arthritis (IA) and those with systemic lupus erythematosus (SLE), undergoing elective total hip arthroplasty (THA) or elective total knee arthroplasty (TKA).MethodsWe convened a panel of rheumatologists, orthopedic surgeons, and infectious disease specialists, updated the systematic literature review, and included currently available medications for the clinically relevant population, intervention, comparator, and outcomes (PICO) questions. We used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology to rate the quality of evidence and the strength of recommendations using a group consensus process.ResultsThis guideline updates the 2017 recommendations for perioperative use of disease‐modifying antirheumatic therapy, including traditional disease‐modifying antirheumatic drugs, biologic agents, targeted synthetic small‐molecule drugs, and glucocorticoids used for adults with rheumatic diseases, specifically for the treatment of patients with IA, including rheumatoid arthritis and spondyloarthritis, those with juvenile idiopathic arthritis, or those with SLE who are undergoing elective THA or TKA. It updates recommendations regarding when to continue, when to withhold, and when to restart these medications and the optimal perioperative dosing of glucocorticoids.ConclusionThis updated guideline includes recently introduced immunosuppressive medications to help decision‐making by clinicians and patients regarding perioperative disease‐modifying medication management for patients with IA and SLE at the time of elective THA or TKA.
eQTL Set–Based Association Analysis Identifies Novel Susceptibility Loci for Barrett Esophagus and Esophageal Adenocarcinoma
Wang, Xiaoyu , Gharahkhani, Puya , Levine, David , Fitzgerald, Rebecca C. , Corley, Douglas A. , Risch, Harvey A. , Bernstein, Leslie , Chow, Wong‐Ho , Onstad, Lynn , Shaheen, Nicholas J. , Lagergren, Jesper , Hardie, Laura J. , Wu, Anna H. , Liu, Geoffrey , Anderson, Lesley , Iyer, Prasad G. , Gammon, Marilie D. , Caldas, Carlos , Ye, Weimin , Barr, Hugh , Harrison, Rebecca , Watson, R.G. Peter , Attwood, Stephen , Chegwidden, Laura , Love, Sharon , MacDonald, David , Prenen, Hans , Ott, Katja , Lang, Hauke , Mayershofer, Rupert , Knapp, Michael , Veits, Lothar , Gerges, Christian , Weismüller, Josef , Reeh, Matthias , Nöthen, Markus M. , Izbicki, Jakob R. , Manner, Hendrik , Neuhaus, Horst , Böhmer, Anne C. , Hölscher, Arnulf H. , Anders, Mario , Pech, Oliver , Schumacher, Brigitte , Schmidt, Claudia , Noder, Tania , Lorenz, Dietmar , Vieth, Michael , May, Andrea , Kreuser, Nicole , Becker, Jessica , Ell, Christian , Tomlinson, Ian , Palles, Claire , Whiteman, David C. , MacGregor, Stuart , Schumacher, Johannes , Vaughan, Thomas L. , Buas, Matthew F. , Dai, James Y. , Levine, David M , Gockel, Ines , Corley, Douglas A , Risch, Harvey A , Bernstein, Leslie , Chow, Wong-Ho , Onstad, Lynn , Shaheen, Nicholas J , Lagergren, Jesper , Hardie, Laura J , Wu, Anna H. , Pharoah, Paul D P , Liu, Geoffrey , Anderson, Lesley A , Iyer, P G , Caldas, Carlos , Ye, Weimin , Barr, Hugh , Moayyedi, Paul , Harrison, Rebecca , Watson, R G Peter , Attwood, Stephen , Chegwidden, Laura , Love, Sharon B , MacDonald, David , deCaestecker, John , Prenen, Hans , Ott, Katja , Moebus, Susanne , Venerito, Marino , Lang, Hauke , Mayershofer, Rupert , Knapp, Michael , Veits, Lothar , Gerges, Christian , Weismüller, Josef , Reeh, Matthias , Nöthen, Markus M , Izbicki, Jakob R , Manner, Hendrik , Neuhaus, Horst , Rösch, Thomas , Böhmer, Anne C , Hölscher, Arnulf H , Anders, Mario , Pech, Oliver , Schumacher, Brigitte , Schmidt, Claudia , Schmidt, Thomas , Noder, Tania , Lorenz, Dietmar , Vieth, Michael , May, Andrea , Hess, Timo , Kreuser, Nicole , Becker, Jessica , Ell, Christian , Tomlinson, Ian , Palles, Claire , Jankowski, Janusz A , Whiteman, David C , MacGregor, Stuart , Schumacher, Johannes , Vaughan, Thomas L , Buas, Matthew F , Dai, James Y , Gharahkhani, Puya , Pharoah, Paul D.P. , Moayyedi, Paul , Caestecker, John de , Moebus, Susanne , Hess, Timo , Jankowski, Janusz

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | June 16, 2022 | Volume: 31 | Issue: 9 | Pages: 1735-1745

10.1158/1055-9965.epi-22-0096 | PMID 35709760 Get It

Abstract Background: Over 20 susceptibility single-nucleotide polymorphisms (SNP) have been identified for esophageal adenocarcinoma (EAC) and its precursor, Barrett esophagus (BE), explaining a small portion of heritability. Methods: Using genetic data from 4,323 BE and 4,116 EAC patients aggregated by international consortia including the Barrett's and Esophageal Adenocarcinoma Consortium (BEACON), we conducted a comprehensive transcriptome-wide association study (TWAS) for BE/EAC, leveraging Genotype Tissue Expression (GTEx) gene-expression data from six tissue types of plausible relevance to EAC etiology: mucosa and muscularis from the esophagus, gastroesophageal (GE) junction, stomach, whole blood, and visceral adipose. Two analytical approaches were taken: standard TWAS using the predicted gene expression from local expression quantitative trait loci (eQTL), and set-based SKAT association using selected eQTLs that predict the gene expression. Results: Although the standard approach did not identify significant signals, the eQTL set–based approach identified eight novel associations, three of which were validated in independent external data (eQTL SNP sets for EXOC3, ZNF641, and HSP90AA1). Conclusions: This study identified novel genetic susceptibility loci for EAC and BE using an eQTL set–based genetic association approach. Impact: This study expanded the pool of genetic susceptibility loci for EAC and BE, suggesting the potential of the eQTL set–based genetic association approach as an alternative method for TWAS analysis.
Abstract CT165: Primary analysis of phase 2 results for cemiplimab in patients with metastatic basal cell carcinoma who progressed on or were intolerant to hedgehog inhibitors
Lewis, Karl D. , Peris, Ketty , Stratigos, Alexander , Dunn, Lara , Eroglu, Zeynep, Migden, Michael R. , Yoo, Suk‐Young, Mohan, Kosalai Kal, Coates, Ebony, Bowler, Timothy G., Bechter, Oliver , Hernandez‐Aya, Leonel F. , Ruiz, Emily S. , Seebach, Frank, Yancopoulos, George D., Lowy, Israel , Gonçalves, Priscila , Fury, Matthew G., Sekulic, Aleksander , Eroglu, Zeynep , Chang, Anne Lynn S. , Okoye, Emmanuel, Baurain, Jean‐François , Hauschild, Axel , Butler, Marcus O. , Licitra, Lisa , Neves, Rogerio I. , Weinreich, David M.

Mayo Clinic

Cancer Research | June 15, 2022 | Volume: 82 | Issue: 12_Supplement | Pages: CT165-CT165

10.1158/1538-7445.am2022-ct165 Get It

Abstract Background: Cemiplimab is the first treatment approved in the US (as cemiplimab-rwlc) for patients with metastatic basal cell carcinoma (mBCC) or locally advanced disease (laBCC) after hedgehog inhibitor (HHI) treatment or for whom an HHI is not appropriate. Cemiplimab provided substantial clinical benefit and an acceptable safety profile in patients with laBCC who discontinued HHI therapy due to progressive disease (PD), intolerance, or no better than stable disease (SD) after 9 months (NCT03132636). Here, we present the primary analysis of the mBCC cohort. Methods: Patients with mBCC (nodal or distant) post-HHI treatment received cemiplimab 350 mg intravenously every 3 weeks for up to 93 weeks or until PD. The primary endpoint was objective response rate (ORR) by independent central review (ICR). Key secondary endpoints included safety and tolerability, ORR per investigator (INV) assessment, duration of response (DOR), progression-free survival (PFS), overall survival (OS), and complete response (CR) rate (data cutoff date: May 20, 2021). Results: Fifty-four patients were enrolled (70.4% male; median age 63.5 years [range, 38−90]; Eastern Cooperative Oncology Group performance status 0 [66.7%] and 1 [33.3%]). Median duration of follow-up was 8.4 months (range 1.5-36.2). ORR per ICR was 24.1% (95% confidence interval [CI], 13.5-37.6); with 1 CR and 12 partial responses (PRs). ORR per INV was 25.9% (95% CI, 15.0-39.7), with 2 CRs and 12 PRs. Among responders, median time to response per ICR was 4.0 months (range, 2.0−10.5). Estimated median DOR per ICR was 16.7 months (95% CI, 9.8-not evaluable). Disease control rate was 63.0% (95% CI, 48.7-75.7) per ICR and 70.4% (95% CI, 56.4-82.0) per INV. Median OS was not reached. Median PFS per ICR was 8.3 months (95% CI, 4.2-15.9). The most common treatment-related adverse events were fatigue (37.0%), diarrhea (14.8%), pruritus (13.0%), hyperthyroidism (9.3%), and arthralgia (9.3%) as well as hypothyroidism, asthenia, constipation, and maculo-papular rash (7.4% each). There were no treatment-related deaths. Conclusions: Cemiplimab provided clinically meaningful antitumor activity, including durable responses, and an acceptable safety profile in patients with mBCC who had progressed on or were intolerant to HHI therapy. Citation Format: Karl Lewis, Ketty Peris, Aleksander Sekulic, Alexander J. Stratigos, Lara Dunn, Zeynep Eroglu, Anne Lynn S. Chang, Michael R. Migden, Suk-Young Yoo, Kosalai Mohan, Ebony Coates, Emmanuel Okoye, Timothy Bowler, Jean-François Baurain, Oliver Bechter, Axel Hauschild, Marcus O. Butler, Leonel Hernandez-Aya, Lisa Licitra, Rogerio I. Neves, Emily S. Ruiz, Frank Seebach, David M. Weinreich, George D. Yancopoulos, Israel Lowy, Priscila Goncalves, Matthew G. Fury. Primary analysis of phase 2 results for cemiplimab in patients with metastatic basal cell carcinoma who progressed on or were intolerant to hedgehog inhibitors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr CT165.
Longitudinal Retinal Changes in MOGAD
Oertel, Frederike Cosima , Sotirchos, Elias S. , Zimmermann, Hanna , Motamedi, Seyedamirhosein , Specovius, Svenja , Asseyer, Eva Susanna, Chien, Claudia , Cook, Lawrence J. , Vasileiou, Eleni S. , Filippatou, Angeliki , D’Cunha, Anitha , Pittock, Sean J. , Bhatti, M. Tariq , Rommer, Paulus , Bsteh, Gabriel , Zrzavy, Tobias , Kuempfel, Tania, Aktaş, Orhan , Ringelstein, Marius , Ayzenberg, Ilya , Pakeerathan, Thivya , Knier, Benjamin , Asgari, Nasrin , Soelberg, Kerstin , Marignier, Romain , Tilikete, Caroline , Calvo, Álvaro Cobo, Villoslada, Pablo , Sánchez‐Dalmau, Bernardo , Green, Ari , Brandt, Alexander U. , Chen, John , Paul, Friedemann , Palace, Jacqueline , Chen, John J. , Asseyer, Susanna , Huda, Saif , Zimmermann, Hanna G , Vasileiou, Eleni , Calabresi, Peter A , Pandit, Lekha , Zéphir, Hélène , Pittock, S J , Bsteh, Gabriel , Zrzavy, Tobias , Kuempfel, Tania , Ringelstein, Marius , Albrecht, Philipp , Knier, Benjamin , Aly, Lilian , Marignier, Romain , Villoslada, Pablo , Brandt, Alexander U , Paul, Friedemann , Chen, John J , Sotirchos, Elias S , Oertel, Frederike C , Palace, Jacqueline , Rommer, Paulus S , Filippatou, Angeliki G , Cook, Lawrence J , Calabresi, Peter A. , Saidha, Shiv , Pandit, Lekha , Outteryck, Olivier , Flanagan, Eoin P. , Kümpfel, Tania , Martínez‐Lapiscina, Elena H. , Llufriú, Sara , Yeaman, Michael R , Smith, Terry J. , Havla, Joachim

Mayo Clinic

Annals of Neurology | June 15, 2022 | Volume: 92 | Issue: 3 | Pages: 476-485

10.1002/ana.26440 | PMID 35703428 Get It

ObjectivePatients with myelin oligodendrocyte glycoprotein antibody (MOG‐IgG)‐associated disease (MOGAD) suffer from severe optic neuritis (ON) leading to retinal neuro‐axonal loss, which can be quantified by optical coherence tomography (OCT). We assessed whether ON‐independent retinal atrophy can be detected in MOGAD.MethodsEighty patients with MOGAD and 139 healthy controls (HCs) were included. OCT data was acquired with (1) Spectralis spectral domain OCT (MOGAD: N = 66 and HCs: N = 103) and (2) Cirrus high‐definition OCT (MOGAD: N = 14 and HCs: N = 36). Macular combined ganglion cell and inner plexiform layer (GCIPL) and peripapillary retinal nerve fiber layer (pRNFL) were quantified.ResultsAt baseline, GCIPL and pRNFL were lower in MOGAD eyes with a history of ON (MOGAD‐ON) compared with MOGAD eyes without a history of ON (MOGAD‐NON) and HCs (p < 0.001). MOGAD‐NON eyes had lower GCIPL volume compared to HCs (p < 0.001) in the Spectralis, but not in the Cirrus cohort. Longitudinally (follow‐up up to 3 years), MOGAD‐ON with ON within the last 6–12 months before baseline exhibited greater pRNFL thinning than MOGAD‐ON with an ON greater than 12 months ago (p < 0.001). The overall MOGAD cohort did not exhibit faster GCIPL thinning compared with the HC cohort.InterpretationOur study suggests the absence of attack‐independent retinal damage in patients with MOGAD. Yet, ongoing neuroaxonal damage or edema resolution seems to occur for up to 12 months after ON, which is longer than what has been reported with other ON forms. These findings support that the pathomechanisms underlying optic nerve involvement and the evolution of OCT retinal changes after ON is distinct in patients with MOGAD. ANN NEUROL 2022;92:476–485
Three-Dimensional Modeling for Augmented and Virtual Reality–Based Posterior Fossa Approach Selection Training: Technical Overview of Novel Open-Source Materials
Graffeo, Christopher S. , Perry, Avital , Nguyen, Bachtri T. , Alexander, Amy E. , Holroyd, Michael J., Peris‐Celda, Maria , Driscoll, Colin L. W., Link, Michael J., Carlstrom, Lucas P. , Nguyen, Bachtri , Link, Michael J. , Morris, Jonathan M.

Mayo Clinic

Operative Neurosurgery | June 15, 2022 | Volume: 22 | Issue: 6 | Pages: 409-424

10.1227/ons.0000000000000154 | PMID 35867081 Get It

BACKGROUND: Selection of skull base approaches is a critical skill for complex cranial surgery, which demands nuanced understanding of neuroanatomy and pathology. OBJECTIVE: To develop novel pedagogical resources for approach selection education and assessment. METHODS: A prospectively maintained skull base registry was screened for posterior fossa tumors amenable to 3-dimensional (3D) modeling of multiple operative approaches. Inclusion criteria were high-resolution preoperative and postoperative computed tomography and MRI studies (≤1 mm) and consensus that at least 3 posterior fossa craniotomies would provide feasible access. Cases were segmented using Mimics and modeled using 3-Matic. Clinical Vignettes, Approach Selection Questionnaire, and Clinical Application Questionnaire were compiled for implementation as a teaching/testing tool. RESULTS: Seven cases were selected, each representing a major posterior fossa approach group. 3D models were rendered using clinical imaging for the primary operative approach, as well as a combination of laboratory neuroanatomic data and extrapolation from comparable craniotomies to generate 2 alternative approaches in each patient. Modeling data for 3D figures were uploaded to an open-sourced database in a platform-neutral fashion (.x3d) for virtual/augmented reality and 3D printing applications. A semitransparent model of each approach without pathology and with key deep structures visualized was also modeled and included for comprehensive understanding. CONCLUSION: We report a novel series of open-source 3D models for skull base approach selection training, with supplemental resources. To the best of our knowledge, this is the first such series designed for pedagogical purposes in skull base surgery or centered on open-source principles.
Isotretinoin Laboratory Monitoring in Acne Treatment
Xia, Eric , Han, Jane , Faletsky, Adam , Baldwin, Hilary , Beleznay, Katie, Dréno, Brigitte , Goh, Chee Leok, Gold, Linda Stein , Gollnick, Harald , Herane, María Isabel, Kang, Sewon , Kircik, Leon , Mann, Julianne A. , Nast, Alexander , Oon, Hazel H. , See, Jo Ann, Tollefson, Megha M. , Webster, Guy, Zip, Catherine, Tapper, Elliot B. , Thiboutot, Diane , Zaenglein, Andrea L. , Barbieri, John S. , Bettoli, Vincenzo , See, Jo‐Ann , Tan, Jerry K.L. , Mostaghimi, Arash

Mayo Clinic

JAMA Dermatology | June 15, 2022 | Volume: 158 | Issue: 8 | Pages: 942

10.1001/jamadermatol.2022.2044 | PMID 35704293 Get It

Importance Although isotretinoin may rarely be associated with laboratory abnormalities such as hypertriglyceridemia, the optimal approach to laboratory monitoring is uncertain, and there is wide variation in clinical practice. Objective To establish a consensus for isotretinoin laboratory monitoring among a diverse, international cohort of clinical and research experts in acne. Design, Setting, and Participants Using a modified electronic Delphi process, 4 rounds of anonymous electronic surveys were administered from 2021 to 2022. For laboratory tests reaching consensus (≥70% agreement) for inclusion, questions regarding more time-specific monitoring throughout isotretinoin therapy were asked in subsequent rounds. The participants were international board-certified dermatologist acne experts who were selected on a voluntary basis based on involvement in acne-related professional organizations and research. Main Outcomes and Measures The primary outcome measured was whether participants could reach consensus on key isotretinoin laboratory monitoring parameters. Results The 22 participants from 5 continents had a mean (SD) time in practice of 23.7 (11.6) years and represented a variety of practice settings. Throughout the 4-round study, participation rates ranged from 90% to 100%. Consensus was achieved for the following: check alanine aminotransferase within a month prior to initiation (89.5%) and at peak dose (89.5%) but not monthly (76.2%) or after treatment completion (73.7%); check triglycerides within a month prior to initiation (89.5%) and at peak dose (78.9%) but not monthly (84.2%) or after treatment completion (73.7%); do not check complete blood cell count or basic metabolic panel parameters at any point during isotretinoin treatment (all >70%); do not check gamma-glutamyl transferase (78.9%), bilirubin (81.0%), albumin (72.7%), total protein (72.7%), low-density lipoprotein (73.7%), high-density lipoprotein (73.7%), or C-reactive protein (77.3%). Conclusions and Relevance This Delphi study identified a core set of laboratory tests that should be evaluated prior to and during treatment with isotretinoin. These results provide valuable data to guide clinical practice and clinical guideline development to optimize laboratory monitoring in patients treated with isotretinoin.
Racial Disparities in the Utilization of Shoulder Arthroplasty in the United States
Farley, Kevin X. , Dawes, Alexander , Wilson, Jacob M. , Toston, Roy J. , Hurt, John , Gottschalk, Michael B. , Navarro, Ronald A. , Dawes, Alexander M , Hurt, John T , Wagner, Eric R , Wagner, Eric R.

Mayo Clinic

JBJS Open Access | June 14, 2022 | Volume: 7 | Issue: 2 | Pages: No page available

10.2106/jbjs.oa.21.00144 | PMID 35673617 Get It

Background: As the incidence of shoulder arthroplasty rises at exponential rates, race is an important consideration, as racial disparities have been reported in lower-extremity arthroplasty in the United States. Our study sought to examine these disparities. Methods: Using the National Inpatient Sample (NIS) database, all anatomic total shoulder arthroplasty (aTSA) and reverse total shoulder arthroplasty (RSA) procedures from 2011 to 2017 were analyzed. The patients were divided into the Black, Hispanic, and White groups. Results: Overall, 91.4% of the patients undergoing any shoulder arthroplasty procedure were White, 4.75% were Black, and 3.85% were Hispanic. Age and sex-standardized RSA utilization rates (per 100,000) in White patients increased by 139% from 6.94 in 2011 to 16.60 in 2017. The disparity for Black patients, compared with White patients, was 118% in 2011 and 124% in 2017; the disparity for Hispanic patients was 112% in 2011 and 103% in 2017. Similar disparities in aTSA utilization rates were seen; when compared with White patients, there was a 150% disparity in 2011 and a 197% disparity in 2017 for Black patients, and a 169% disparity in 2011 and a 262% disparity in 2017 for Hispanic patients. Finally, Blacks had a higher rate of non-home discharge, longer length of stay, and higher overall costs, while Hispanics had a longer length of stay and higher cost than Whites. Conclusions: Despite many efforts to reduce racial disparities in health-care utilization, the chasm in shoulder arthroplasty in the United States appears to be large and widening further. The exponential increase in utilization of shoulder arthroplasty has not been shared equally among races, and the disparities are larger than those reported in lower-extremity arthroplasty.
Prospective evaluation of lymphatic embolization as part of the treatment in dogs with presumptive idiopathic chylothorax
Carvajal, Jose L. , Case, J. Brad , Grosso, Federico R. Vilaplana , Fox‐Alvarez, W. Alexander, Regier, Penny J. , Verpaalen, Valentine D. , Toskich, Beau B. , Verpaalen, Valentine

Mayo Clinic

Veterinary Surgery | June 13, 2022 | Volume: 51 | Issue: S1 | Pages: No page available

10.1111/vsu.13825 | PMID 35692101 Get It

AbstractObjectiveTo describe the embolization technique and short‐term clinical outcome in dogs undergoing lymphatic embolization (LE) as part of treatment for presumptive idiopathic chylothorax (IC). Additionally, to document findings in computed tomography lymphangiography (CTLa) following embolization.Study designProspective case series.AnimalsEight client‐owned dogs.MethodsDogs underwent CTLa followed by thoracic duct ligation (TDL), pericardiectomy (PC) and LE. A mixture of 3:1 lipiodol: n‐butyl cyanoacrylate embolic solution was injected through a catheterized mesenteric lymphatic vessel via limited abdominal approach using intraoperative fluoroscopy. CTLa was scheduled for 12 weeks postoperatively, and long‐term follow‐up was obtained via telephone contact.ResultsLE was technically successful in six of the eight dogs; and clinically successful in five of the six dogs. In the unsuccessful dog, a diagnosis of lymphangiosarcoma was determined, and the owners elected for euthanasia. Five dogs who underwent successful LE underwent CTLa at 12 weeks. Complete resolution of pleural effusion occurred in three dogs and scant pleural effusion in two dogs. A robust lymphatic embolus preventing antegrade continuation of radiocontrast was documented in all five dogs. Five of the six dogs that underwent LE, were alive and clinically normal at 358–960 days postoperatively.ConclusionsLE is a feasible part of treatment for dogs with IC. Additionally, a robust lymphatic embolus and lack of radiocontrast flow past the embolus was documented at 12 weeks following surgery.Clinical significanceLE has the potential to reduce surgical failure by reducing efferent lymphatic chyle flow, occluding missed lymphatic branches and preventing the development of collateral branches.